Premium
Human T‐cell leukemia virus type I–associated myelopathy following living‐donor liver transplantation
Author(s) -
Soyama Akihiko,
Eguchi Susumu,
Takatsuki Mitsuhisa,
Ichikawa Tatsuki,
Moriuchi Masako,
Moriuchi Hiroyuki,
Nakamura Tatsufumi,
Tajima Yoshitsugu,
Kanematsu Takashi
Publication year - 2008
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.21414
Subject(s) - medicine , liver transplantation , leukemia , myelopathy , transplantation , virology , immunology , spinal cord , psychiatry
This report describes a patient who developed human T‐cell leukemia virus type I–associated myelopathy (HAM) following a living‐donor liver transplantation (LDLT) for liver cirrhosis due to hepatitis C virus (HCV) infection. Both the recipient and the living donor (his sister) were human T‐cell leukemia virus type I (HTLV‐I) carriers. Since the LDLT, he had been treated with immunosuppressive drugs such as tacrolimus and steroids as well as interferon‐α to prevent rejection and a recurrence of the HCV infection, respectively. Even though the HTLV‐I proviral load had decreased upon interferon treatment, he developed a slowly progressive gait disturbance with urinary disturbance 2 years after the LDLT and was diagnosed with HAM. This appears to be the first report of HAM development in an HLTV‐I–infected LDLT recipient. Liver Transpl 14:647–650, 2008. © 2008 AASLD.